BridgeBio Pharma, Inc. at Morgan Stanley Global Healthcare Conference Transcript
Good morning, everyone. I'm Sean Laaman, Head of US Mid-cap Biotech Equity Research here at Morgan Stanley, and welcome to the Morgan Stanley Global Healthcare Conference. Before we commence, I'll make you aware of some important disclosures. For those disclosures, please visit the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures.
And if you have any questions, please reach out to your Morgan Stanley sales representative. For this session, we have the pleasure of hosting Bridge Biopharma with Julie Everett, COO of BridgeBio Skeletal Dysplasia and Chief Business Officer, Chinmay Shukla. Welcome to both of you, and thank you for your time today.
Questions & Answers
I've got some macro considerations. We're just talking about interest rates offline, but just some macro considerations to discuss before we really dig in on Bridge. But how is the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
